IDMA plans extensive workshops on revised Schedule M to assist pharma MSMEs

With revision in extension of the deadline for implementing the revised Schedule M until December 31, 2025, the Indian Drug Manufacturers’ Association (IDMA) has announced plans to intensify its capacity-building initiatives to help pharmaceutical micro, small, and medium enterprises (MSMEs) and larger players to align with the revised Schedule M guidelines. These measures aim to elevate the quality of medicines produced in India to meet global regulatory standards. The Union ministry of health had extended the deadline through a draft notification on January 4, 2025, enabling small and medium manufacturers with turnovers below Rs. 250 crore to seek timeline extensions. The extension allows smaller manufacturers additional time to upgrade facilities and align with global quality standards.